Metabolomic Fingerprints of Medical Therapy Versus Bariatric Surgery in Patients With Obesity and Type 2 Diabetes: The STAMPEDE Trial
Diabetes Care · 01.11.2024 · 47 (11) · 2024-2032
DOI: 10.2337/dc24-0859 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 23.09.2024. Verfasst von Christopher L Axelrod und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Gastric Bypass, Bariatric Surgery. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: LifeScan, NIDDK NIH HHS, Cleveland Clinic.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are effective procedures to treat and manage type 2 diabetes (T2D). However, the underlying metabolic adaptations that mediate improvements in glucose homeostasis remain largely elusive. The purpose of this study was to identify metabolic signatures associated with biochemical resolution of T2D after medical therapy (MT) or bariatric surgery. RESEARCH DESIGN AND METHODS Plasma samples from 90 patients (age 49.9 ± 7.6 years; 57.7% female) randomly assigned to MT (n = 30), RYGB (n = 30), or SG (n = 30) were retrospectively subjected to untargeted metabolomic analysis using ultra performance liquid chromatography with tandem mass spectrometry at baseline and 24 months of treatment. Phenotypic importance was determined by supervised machine learning. Associations between change in glucose homeostasis and circulating metabolites were assessed using a linear mixed effects model. RESULTS The circulating metabolome was dramatically remodeled after SG and RYGB, with largely overlapping signatures after MT. Compared with MT, SG and RYGB profoundly enhanced the concentration of metabolites associated with lipid and amino acid signaling, while limiting xenobiotic metabolites, a function of decreased medication use. Random forest analysis revealed 2-hydroxydecanoate as having selective importance to RYGB and as the most distinguishing feature between MT, SG, and RYGB. To this end, change in 2-hydroxydecanoate correlated with reductions in fasting glucose after RYGB but not SG or MT. CONCLUSIONS We identified a novel metabolomic fingerprint characterizing the longer-term adaptations to MT, RYGB, and SG. Notably, the metabolomic profiles of RYGB and SG procedures were distinct, indicating equivalent weight loss may be achieved by divergent effects on metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
- Integrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA.
- Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, OH.
- Clinical Metabolic Surgery Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA.
ORCID-Profile: John P Kirwan
Förderung
- LifeScan
- NIDDK NIH HHS
- Cleveland Clinic
- Ethicon Endo-Surgery
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Axelrod, C. L., Hari, A., Dantas, W. S., Kashyap, S. R., Schauer, P. R., & Kirwan, J. P. (2024). Metabolomic Fingerprints of Medical Therapy Versus Bariatric Surgery in Patients With Obesity and Type 2 Diabetes: The STAMPEDE Trial. Diabetes Care, 47(11), 2024-2032. https://doi.org/10.2337/dc24-0859
Vancouver
Axelrod CL, Hari A, Dantas WS, Kashyap SR, Schauer PR, Kirwan JP. Metabolomic Fingerprints of Medical Therapy Versus Bariatric Surgery in Patients With Obesity and Type 2 Diabetes: The STAMPEDE Trial. Diabetes Care. 2024;47(11):2024-2032. doi:10.2337/dc24-0859
BibTeX
@article{Axelrod2024,
author = {Axelrod, Christopher L and Hari, Adithya and Dantas, Wagner S and Kashyap, Sangeeta R and Schauer, Philip R and Kirwan, John P},
title = {Metabolomic Fingerprints of Medical Therapy Versus Bariatric Surgery in Patients With Obesity and Type 2 Diabetes: The STAMPEDE Trial},
journal = {Diabetes Care},
year = {2024},
volume = {47},
number = {11},
pages = {2024--2032},
doi = {10.2337/dc24-0859}
}
EUVIMED